Sustained weight loss protects against breast cancer, FDA supports another indication for Keytruda — top stories in hematology/oncology
Click Here to Manage Email Alerts
A recent study showed that women aged 50 years and older with sustained weight loss for longer than 8 years had a decreased risk for breast cancer — giving clinicians even more reason to recommend that their patients lose weight and keep it off. This was one of the top stories last week in hematology/oncology.
News that an FDA advisory committee voted to support the approval of Keytruda for patients with high-risk bladder cancer was another top story.
Sustained weight loss lowers risk for breast cancer
Women aged 50 years and older who had sustained weight loss over more than 8 years demonstrated a decreased risk for breast cancer compared with women whose weight remained stable, according to results of a pooled analysis published in Journal of the National Cancer Institute. Read more.
FDA advisory committee supports approval of Keytruda for high-risk bladder cancer
An FDA advisory committee voted to support the approval of pembrolizumab for the treatment of patients with bacillus Calmette-Guérin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Read more.
Circulating tumor DNA predicts recurrence in early-stage triple-negative breast cancer
Detection of circulating tumor DNA after neoadjuvant chemotherapy appeared to independently predict disease recurrence among women with early-stage triple-negative breast cancer, according to preplanned analyses of results from the randomized phase 2 BRE12-158 trial presented at San Antonio Breast Cancer Symposium. Read more.
Daratumumab-based triplet regimen extends PFS in advanced multiple myeloma
A novel triple-agent combination of carfilzomib, dexamethasone and daratumumab outperformed carfilzomib plus dexamethasone in terms of PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to results of the randomized phase 3 CANDOR trial presented during the late-breaking abstract session of ASH Annual Meeting and Exposition. Read more.
FDA grants breakthrough therapy designation to tucatinib for advanced breast cancer
The FDA granted breakthrough therapy designation to tucatinib, in combination with trastuzumab and capecitabine, for the treatment of locally advanced unresectable or metastatic HER2-positive breast cancer, according to a press release from the agent's manufacturer. Read more.